Published in Clin Infect Dis on February 01, 1993
Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin Diagn Lab Immunol (1994) 2.08
New insights into human cryptosporidiosis. Clin Microbiol Rev (1999) 1.72
Detection of Cryptosporidium parvum DNA in formed human feces by a sensitive PCR-based assay including uracil-N-glycosylase inactivation. J Clin Microbiol (1997) 1.00
Human intestinal and biliary cryptosporidiosis. World J Gastroenterol (1999) 0.86
Use of paromomycin for the treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 0.86
Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev (1995) 0.84
Cryptosporidium parvum-specific CD4 Th1 cells from sensitized donors responding to both fractionated and recombinant antigenic proteins. Infect Immun (2004) 0.82
Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model. Antimicrob Agents Chemother (1994) 0.80
Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study. Antimicrob Agents Chemother (1995) 0.79
Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model. Antimicrob Agents Chemother (1995) 0.78
Synergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycin. Antimicrob Agents Chemother (1997) 0.76
Parasitic infections of the small intestine. Gut (1994) 0.75
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med (1999) 2.53
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol (1998) 1.27
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 1.22
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab (2005) 1.21
Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med (2006) 1.21
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 1.15
Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.13
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis (2000) 1.12
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med (1993) 1.11
Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol (1995) 1.10
In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother (1995) 1.10
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med (1998) 1.09
Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1992) 1.09
Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis (1995) 1.07
Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab (2003) 1.06
Exposure of mice to live Pseudomonas aeruginosa generates protective cell-mediated immunity in the absence of an antibody response. J Immunol (1988) 1.05
Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis (1999) 1.02
Pneumococcal endocarditis: report of a series and review of the literature. Rev Infect Dis (1986) 1.02
Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis (1995) 1.00
Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS (2000) 1.00
Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis (1994) 0.97
T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice. J Clin Invest (1986) 0.96
Fellowship training in infectious diseases: a report from the regional and national meetings of infectious diseases division chiefs and program directors. Clin Infect Dis (1998) 0.96
Vancomycin levels after intravitreal injection. Effects of inflammation and surgery. Retina (1995) 0.95
Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol (1985) (2001) 0.95
Intraocular injection of ceftazidime. Effects of inflammation and surgery. Retina (1995) 0.94
A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy (1997) 0.94
Two cases of blastomycosis from a common source: use of DNA restriction analysis to identify strains. J Infect Dis (1991) 0.94
Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis (1992) 0.91
Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome. HIV Med (2009) 0.90
Cryptococcal disease: implications of recent clinical trials on treatment and management. AIDS Clin Rev (1997) 0.89
Suppressor T cells regulating the cell-mediated immune response to Pseudomonas aeruginosa can be generated by immunization with anti-bacterial T cells. J Immunol (1988) 0.87
The changing face of mycoses in patients with HIV/AIDS. AIDS Read (2001) 0.87
Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin Chem (1994) 0.87
Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease? HIV Med (2007) 0.87
USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis (1995) 0.86
Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis (2001) 0.85
Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat (2007) 0.85
In vitro T cell-mediated killing of Pseudomonas aeruginosa. V. Generation of bactericidal T cells in nonresponder mice. J Immunol (1987) 0.84
Editorial response: management of cryptococcal meningitis--have we answered all the questions? Clin Infect Dis (1996) 0.84
Hypothalamic-pituitary-adrenal function in patients receiving intermittent high dose prednisone therapy for lymphoma. Ir Med J (1984) 0.83
In vitro T cell-mediated killing of Pseudomonas aeruginosa. IV. Nonresponsiveness in polysaccharide-immunized BALB/c mice is attributable to vinblastine-sensitive suppressor T cells. J Immunol (1986) 0.83
Nelfinavir mesylate. Expert Opin Pharmacother (2000) 0.82
Risks of HIV infection in the health care setting. Annu Rev Med (1995) 0.82
Renal glomerulopathies associated with Hodgkin's disease. Cancer (1985) 0.82
Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism (1997) 0.81
Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. AIDS Res Hum Retroviruses (1993) 0.81
Cryptococcosis. Adv Pharmacol (1997) 0.81
Oesophageal ulceration in Behçet's disease presenting with haemorrhage. Ir J Med Sci (1987) 0.80
In vitro T cell-mediated killing of Pseudomonas aeruginosa. III. The role of suppressor T cells in nonresponder mice. J Immunol (1986) 0.80
Ototoxicity associated with dideoxycytidine. Lancet (1990) 0.79
The use of alternative therapies by HIV-positive patients attending the St. Louis AIDS Clinical Trials Unit. Mo Med (1991) 0.79
Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med (1993) 0.79
Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.78
Molecular epidemiology of mucosal candidiasis in HIV-positive women. AIDS Res Hum Retroviruses (1997) 0.78
Prophylaxis for HIV-related infections: a work in progress. Ann Intern Med (1996) 0.77
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l. AIDS (2001) 0.77
Ganciclovir for cytomegalovirus after heart transplantation. N Engl J Med (1992) 0.77
Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. AIDS (2001) 0.76
Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res Hum Retroviruses (2001) 0.76
The interaction of opportunistic infections and HIV replication. AIDS (1999) 0.76
Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group. Clin Infect Dis (1993) 0.75
Clinical research in the acquired immunodeficiency syndrome. Ann Intern Med (1995) 0.75
Comment: consideration of amphotericin B hepatotoxicity. DICP (1991) 0.75
Major blinding complication of acquired immune deficiency syndrome (AIDS) Retina (1997) 0.75
Rifabutin induced vitritis in AIDS patients. Ocul Immunol Inflamm (1996) 0.75
Ruptured intraventricular dermoid cyst without clinical inflammation. Arch Neurol (1978) 0.75
Progenitor cell types in HIV-1 infection: bioactivity and emerging targets for treatment. Curr HIV Res (2009) 0.75
Lithium fluoride: an inexpensive calibration check for the general hospital. South Med J (1973) 0.75
Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis (1993) 0.75
Diltiazem-induced psychosis and a possible diltiazem-lithium interaction. Arch Intern Med (1991) 0.75
Spontaneous splenic infarction in polysplenia syndrome. J Comput Assist Tomogr (1982) 0.75
Prophylaxis of opportunistic infections. Infect Dis Clin North Am (2000) 0.75
A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.75
Zidovudine. Mo Med (1989) 0.75
Aspergillosis. J Int Assoc Physicians AIDS Care (1997) 0.75
A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clin Infect Dis (1999) 0.75